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OBJECTIVES We assessed the effects of estrogen on vascular dilatory and other homeostatic functions
potentially affected by nitric oxide (NO)-potentiating properties in type II diabetic post-
menopausal women.
BACKGROUND There is a higher cardiovascular risk in diabetic women than in nondiabetic women. This
would suggest that women with diabetes do not have the cardioprotection associated with
estrogen.
METHODS We administered placebo or conjugated equine estrogen, 0.625 mg/day for 8 weeks, to 20
type II diabetic postmenopausal women in a randomized, double-blinded, placebo-controlled,
cross-over design.
RESULTS Compared with placebo, estrogen tended to lower low-density lipoprotein (LDL) cholesterol
levels by 15  23% (p  0.007) and increase high-density lipoprotein (HDL) cholesterol
levels by 8 16% (p 0.034). Thus, the ratio of LDL to HDL cholesterol levels significantly
decreased with estrogen, by 20  24%, as compared with placebo (p  0.001). Compared
with placebo, estrogen tended to increase triglyceride levels by 16  48% and lower
glycosylated hemoglobin levels by 3  13% (p  0.295 and p  0.199, respectively).
However, estrogen did not significantly improve the percent flow-mediated dilatory response
to hyperemia (17  75% vs. placebo; p  0.501). The statistical power to accept our
observation was 81.5%. Compared with placebo, estrogen did not significantly change
E-selectin, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, monocyte
chemoattractant protein-1 or matrix metalloproteinase-9 levels. Compared with placebo,
estrogen tended to decrease tissue factor antigen and increase tissue factor activity levels by
7  46% and 5  34%, respectively (p  0.321 and p  0.117, respectively) and lower
plasminogen activator inhibitor-1 levels by 16  31% (p  0.043).
CONCLUSIONS The effects of estrogen on endothelial, vascular dilatory and other homeostatic functions were
less apparent in type II diabetic postmenopausal women, despite the beneficial effects of
estrogen on lipoprotein levels. (J Am Coll Cardiol 2001;38:1409–15) © 2001 by the
American College of Cardiology
Prospective cohort surveys, such as the Nurses’ Health
Study, suggest that estrogen therapy decreases the risk of
coronary artery disease (CAD) in postmenopausal women
who were initially healthy at the time of enrollment (1). The
atheroprotective effects of estrogen were principally attrib-
uted to the hormone’s effects on serum lipid concentrations
(2,3). However, estrogen-induced alterations in serum lipids
account for only approximately one-third of the observed
clinical benefits of estrogen (4). Other mechanisms of the
potential benefit include protection of low-density lipopro-
teins (LDL) from oxidation (5), potentiation of fibrinolysis
(6) and improvement in endothelium-dependent vasodila-
tory function due to increased nitric oxide (NO) bioavail-
ability (7–9). The endothelium plays a key role in the
homeostasis of these processes. Therefore, estrogen may
exert its cardiovascular benefits through the regulation of
endothelial function, which is now regarded as pivotal
against atherogenesis (10).
Atherosclerosis, the main cause of coronary heart disease,
occurs with higher than normal frequency in women with
diabetes and is the major cause of morbidity and mortality in
diabetic patients (11–13). Therefore, it is important to know
whether estrogen can confer the same cardioprotection in
diabetic women as in healthy women. Epidemiologic data have
revealed that diabetic women have a higher cardiovascular risk,
as compared with diabetic men (14) or nondiabetic women
(13). This would suggest that women with diabetes do not
have the cardioprotection associated with estrogen. In this
regard, people with type II diabetes have significantly increased
serum triglyceride levels and decreased high-density lipopro-
tein (HDL) cholesterol levels (12). Further, the abnormal
HDL composition in type II diabetes has been well studied
and is characterized by triglyceride enrichment, cholesterol
depletion and decreased apolipoprotein A-I concentrations
(15). High plasma triglyceride concentrations and such abnor-
malities in HDL among diabetic subjects appear to be inde-
pendent predictive factors of mortality from CAD (16). In-
deed, one study observed that postmenopausal women with
diabetes who were taking estrogen had an exaggerated hyper-
triglyceridemic response (17). Hyperglycemia appears to con-
tribute to endothelial dysfunction through several mechanisms
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(18–22). Hyperglycemia attenuated the ability of estrogen to
stimulate endothelial cell NO production (18). In this regard,
postmenopausal women with type II diabetes treated with
estrogen had continued impairment of microvascular reactivity,
in contrast to the improved responses with estrogen treatment
of healthy postmenopausal women (19). In type II diabetic
subjects, enhanced LDL oxidation occurs in vivo, because high
titers of autoantibodies to oxidatively modified LDL are
present in the plasma (20). Gowri et al. (21) showed that
HDL2 in diabetic patients did not protect against apolipopro-
tein B-100 fragmentation in LDL, as compared with that in
nondiabetic control subjects. In diabetes mellitus, there is
reduced NO production or increased NO destruction, or both,
which contributes to enhanced platelet aggregation. Further,
both hyperinsulinemia and hyperglycemia contribute to an
imbalance between coagulation and fibrinolysis in individuals
with diabetes (22).
However, there are few reports specifically investigating
whether estrogen can reduce the risk of cardiovascular
disease in type II diabetic postmenopausal women. We have
previously shown that unopposed estrogen improved NO
bioactivity in healthy or hypercholesterolemic postmeno-
pausal women (23,24). Therapies that increase NO bioac-
tivity may reduce synthesis of proinflammatory proteins and
monocyte chemoattractant protein-1 (MCP-1) on the en-
dothelial cell surface (25–27). In this regard, we have
previously shown that oral conjugated equine estrogen
(CEE) improved endothelium-dependent vasodilatory re-
sponsiveness and reduced markers of inflammation (23,24).
Thus, this study was designed to assess the effects of
estrogen on vascular dilatory and other homeostatic func-
tions potentially affected by NO-potentiating properties in
type II diabetic postmenopausal women.
METHODS
Study group and design. Twenty type II diabetic post-
menopausal women (mean [ SD] age 59 7 years) free of
CAD participated in this study, all with plasma 17-
estradiol levels 50 pg/ml and cessation of menses for at
least one year. Baseline total cholesterol, triglyceride, HDL
cholesterol and LDL cholesterol levels were 210  31 mg/dl,
154  70 mg/dl, 52  8 mg/dl and 127  28 mg/dl,
respectively. Baseline body mass index, systolic and diastolic
blood pressure, blood glucose and glycosylated hemoglobin
were 27.4  5.2 kg/m2, 132  11 mm Hg and 77 
11 mm Hg, 162  26 mg/dl and 7.9  0.9%, respectively.
The diagnosis of diabetes was based on a history of diabetes
or criteria according to the Report of the Expert Committee
on the Diagnosis and Classification of Diabetes Mellitus
(28). Participants who met the criteria for entry into the
study entered an eight-week run-in phase during which
there was no alteration of their usual management. To
minimize acute side effects of CEE, the study medication
was titrated upward over a four-week period. At the end of
this time, participants continued to receive one capsule per
day of either placebo or CEE. The patients were seen at
least at 14-day intervals during the study. Sulfonylureas
were discontinued 24 h before the study. None of the
subjects was hypertensive or a current cigarette smoker. No
subject had taken any cholesterol-lowering agent, estrogen
therapy or antioxidant vitamin supplements during the
preceding two months. Aspirin and nonsteroidal anti-
inflammatory agents were stopped beginning 10 days before
the study. This study was randomized, double-blinded,
placebo-controlled and cross-over in design. Study partici-
pants received placebo or CEE, 0.625 mg/day for 8 weeks,
with the second treatment period initiated on completion of
the first treatment period (without a washout phase). The
study was approved by the Gil Hospital Institute Review
Board, and all participants gave written, informed consent.
Laboratory assays. Blood samples for laboratory assays
were obtained at 8:00 AM after overnight fasting, at
baseline and at the end of each treatment period, and were
immediately coded so that the investigators performing the
laboratory assays had no knowledge of the subjects’ identity
or study sequence. Assays for lipids, E-selectin, intercellular
adhesion molecule-1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1) and plasminogen activator
inhibitor-1 (PAI-1) antigen were performed as previously
described (6,23,24,29). Levels of MCP-1 and matrix
metalloproteinase-9 (MMP-9) were measured in duplicate
by enzyme-linked immunosorbent assay (ELISA; R & D
Systems, Minneapolis, Minnesota). Tissue factor (TF) an-
tigen and activity were measured in duplicate by ELISA and
actichrome assays (American Diagnostica, Greenwich,
Connecticut). The interassay and intra-assay coefficients of
variation were 8%.
Vascular studies. Imaging studies of the right brachial
artery were performed using a ATL HDI 3000 (ATL,
Bothell, Washington) ultrasound machine equipped with a
10-MHz linear-array transducer, at baseline and at the end
of each of the two treatment periods, according to a
previously published technique (23,24,29,30). After 15 min
of rest, imaging of the artery proximal to the antecubital
Abbreviations and Acronyms
CAD  coronary artery disease
CEE  conjugated equine estrogen
CI  confidence interval
ELISA  enzyme-linked immunosorbent assay
HERS  Heart and Estrogen/progestin Replacement
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ICAM-1  intercellular adhesion molecule-1
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fossa was done longitudinally, with the center of the artery
identified by the clearest visualization of the anterior and
posterior intimal layers. The transmit (focus) zone was set to
the depth of the near wall. After a satisfactory transducer
position was found, the skin was marked, and the arm
remained in that position throughout the study. A baseline
measurement of brachial artery diameter was made, as well
as a baseline measurement of the velocity of arterial flow by
pulsed Doppler echocardiography, with the range gate
(1.5 mm) in the center of the artery. Endothelium-
dependent vasodilation was assessed by measuring the
change in the diameter of the brachial artery after 60 s of
reactive hyperemia, relative to baseline measurements after
deflation of a forearm cuff inflated to 250 mm Hg for 5 min
(percent flow-mediated dilation). This dilatory response has
previously been shown to be mediated primarily by NO
(31). Arterial flow velocity was measured for the first 15 s
after cuff deflation. After re-establishing baseline conditions
15 min later, measurements of arterial diameter and flow
velocity were repeated, followed by sublingual nitroglycerin
at a dose of 0.4 mg under the tongue to assess endothelium-
independent vasodilation. Three minutes later, repeat mea-
surements of arterial diameter and flow velocity were made.
All images were coded and recorded on super VHS
videotape (Sony, Tokyo, Japan) and stored on the hard disk
of the ATL machine. All images were transmitted to a
personal computer by use of Ethernet (PRETEC, Fremont,
California) with a DICOM (Digital Imaging and Commu-
nication in Medicine) format (Dept. of Radiology, Seoul
National University Hospital, Seoul, Korea) and then saved
on the hard disk of the personal computer as a bitmap
format. Arterial diameters were measured with Image Tool
for Windows, version 2.0 (University of Texas Health
Science Center, San Antonio, Texas). Measurements were
performed by two independent radiologists (S. K. L. and
H. Y. H.) who had no knowledge of the subjects’ identity
and medication status. Arterial diameter was measured in
millimeters as the distance between the anterior wall media-
adventitial interface (m line) and the posterior wall intima-
lumen interface at end diastole, coincident with the R-wave
on the electrocardiogram at two sites along the artery and
for three cardiac cycles, with these six measurements aver-
aged. Blood flow was calculated by multiplying the velocity-
time integral of the Doppler flow signal by the heart rate
and cross-sectional area of the vessel. Measurements of
maximal diameter and percent flow-mediated dilation were
made in 10 studies selected at random. The interobserver
and intraobserver variabilities for repeated measurements of
maximal diameter were 0.004  0.038 and 0.005 
0.091 mm, respectively. The interobserver and intraobserver
variabilities for repeated measurements of percent flow-
mediated dilation were 0.07  1.29% and 0.17  1.26%,
respectively.
Statistical analysis. Data are expressed as the mean
value  SD. After testing data for normality, we used the
Student paired t test or the Wilcoxon signed-rank test to
compare values after placebo and CEE therapies, as re-
ported in Tables 1 and 2. We presumed that the second
baseline value after the washout phase was not different
from the first baseline value, because we found no carryover
effect of CEE for six weeks in our previous studies
(6,23,24,29). Thus, we decided on eight weeks as the
treatment period, without the washout phase and second
baseline study. Indeed, we found no carryover effect in this
study (see the Results section). Pearson correlation coeffi-
cient analysis was used to assess associations between
measured variables. We calculated that 20 subjects will
provide 80% power to detect a difference of an absolute
Table 1. Effects of Placebo or Oral Conjugated Equine
Estrogen on Glycosylated Hemoglobin and Lipid Levels in
Type II Diabetic Postmenopausal Women
Placebo Estrogen
HbA1c (%) 8.0  1.2 7.6  0.9
Lipids (mg/dl)
Total cholesterol 211  39 198  38
HDL cholesterol 52  8 56  10*
LDL cholesterol 129  35 107  33†
LDL/HDL cholesterol 2.55  0.81 1.97  0.65†
Triglycerides 165  83 183  97
*p  0.05 and †p  0.01 vs. placebo. Data are expressed as the mean value  SD.
HbA1c  glycosylated hemoglobin (normal range 2.3% to 7.1%); HDL 
high-density lipoprotein; LDL  low-density lipoprotein.
Table 2. Effects of Placebo or Oral Conjugated Equine
Estrogen on Endothelial Function in Type II Diabetic
Postmenopausal Women
Placebo Estrogen
Vasomotor function
Brachial artery diameter (mm)
Basal-1 4.14  0.57 4.19  0.38
Hyperemia 4.36  0.58 4.45  0.34
Basal-2 4.19  0.54 4.21  0.47
Nitroglycerin 4.63  0.54 4.74  0.51
Brachial artery flow
Basal-1 (ml/min) 86  39 74  35
Hyperemia (ml/min) 425  208 407  144
Increase in flow (%) 469  290 575  390
Basal-2 (ml/min) 65  25 67  38
Nitroglycerin (ml/min) 99  35 92  27
Flow-mediated dilation (%) 5.87  2.37 6.52  4.44
Nitroglycerin dilation (%) 11.26  4.30 13.86  4.56*
Cell adhesion molecules (ng/ml)
E-selectin 68.6  37.7 67.8  36.1
ICAM-1 408  125 435  172
VCAM-1 743  314 735  278
MCP-1 (pg/ml) 182  72 163  51
Hemostasis
TF antigen (pg/ml) 224  103 200  115
TF activity (nmol/l) 0.804  0.145 0.877  0.212
Fibrinolysis
PAI-1 (ng/ml) 36.74  12.27 30.57  16.04*
Plaque stability
MMP-9 (ng/ml) 148.8  98.2 173.8  142.4
*p  0.05 vs. placebo. Data are expressed as the mean value  SD.
ICAM-1  intercellular adhesion molecule-1; MCP-1  monocyte chemoattrac-
tant protein-1; MMP-9  matrix metalloproteinase-9; PAI-1  plasminogen
activator inhibitor-1; TF  tissue factor; VCAM-1  vascular cell adhesion
molecule-1.
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increase of 2.1% or greater flow-mediated dilation of the
brachial artery with CEE as compared with placebo, with
alpha  0.05 according to our previous studies (23,24,29)
and another study (32). A comparison of endothelium-
dependent dilation between placebo and CEE therapies was
prospectively designated as the primary end point of the
study. For a conservative analysis, a p value less than the
Bonferroni-adjusted alpha value of 0.05/24  0.002 was
deemed as statistically significant for each of the 24 variables
that underwent statistical comparison in this study.
RESULTS
To assess the possibility of a carryover effect from the initial
treatment periods to the next treatment period, we com-
pared the percent changes of: 1) the first treatment placebo
and second treatment placebo; and 2) the first treatment
CEE and second treatment CEE, relative to the baseline
values. There were no significant differences in age or
baseline values—vascular function (diameter and flow) and
markers of inflammation, hemostasis, fibrinolysis inhibition
and plaque stability—between each group. No significant
differences were found in these two comparisons (data not
shown).
Effect of therapies on lipids. The effects of therapies on
lipids are shown in Table 1. Compared with placebo, CEE
therapy tended to lower LDL cholesterol levels by 15 
23% (p  0.007) and increase HDL cholesterol levels by
8  16% (p  0.034). Thus, the ratio of LDL to HDL
cholesterol levels significantly decreased with CEE therapy,
by 20  24%, as compared with placebo (p  0.001).
However, CEE therapy tended to increase triglyceride levels
by 16  48% (p  0.295).
Effect of therapies on glycemic control. Therapy with
CEE tended to lower glycosylated hemoglobin levels by 3
13%, as compared with placebo (p  0.199).
Effect of therapies on NO bioactivity. Basal brachial
artery diameters and forearm blood flow rates were similar
to those during the placebo and CEE treatment periods, as
were peak brachial artery diameters and forearm blood flow
rates during reactive hyperemia and the percent increase in
flow during hyperemia (Table 2). However, CEE therapy
did not significantly improve the percent flow-mediated
dilatory response to hyperemia (17  75%), as compared
with placebo (p 0.501). The 95% confidence interval (CI)
for the absolute differences in flow-mediated dilation be-
tween the placebo and CEE therapies was 1.34% to
2.64%. Thus, in our study of 20 subjects, we excluded
unknown values outside the 95% CIs as plausible values for
the differences in the flow-mediated dilatory response to
each therapy, at alpha  0.05. The brachial artery dilatory
response to nitroglycerin was increased with CEE therapy,
by 37 70%, as compared with placebo (p 0.034) (Table 2).
Effect of therapies on markers of inflammation. Com-
pared with placebo, CEE therapy did not significantly
change E-selectin, ICAM-1 or VCAM-1 levels, by 1 
31%, 8  34% and 6  45%, respectively (p  0.890, p 
0.319 and p  0.883, respectively) (Table 2). Therapy with
CEE lowered MCP-1 levels by 4  27% (p  0.121)
(Table 2).
Effect of therapies on hemostasis and fibrinolytic inhibi-
tion. Compared with placebo, CEE therapy tended to
decrease TF antigen and increase TF activity levels by 7 
46% and 5  34%, respectively (p  0.321 and p  0.117,
respectively) (Table 2). Therapy with CEE tended to lower
plasma PAI-1 levels by 16  31%, as compared with
placebo (p  0.043) (Table 2). There was no significant
association between TF antigen or activity levels and PAI-1
antigen levels after placebo or CEE therapies (0.141 all
r  0.056).
Effect of therapies on plaque stability. Compared with
placebo, CEE therapy increased MMP-9 levels by 16 
67% (p  0.693) (Table 2).
DISCUSSION
We investigated the effects of estrogen on lipoproteins and
endothelium in type II diabetic postmenopausal women.
Because endothelial dysfunction may contribute to the
development and clinical expression of atherosclerosis and,
furthermore, the pathogenesis of coronary heart disease, and
because diabetes is associated with endothelial dysfunction,
we have previously shown that estrogen improved impaired
endothelial function in healthy postmenopausal women
(6,23,24,29).
Effect of therapies on lipids and glycemic control. In the
current study, administration of CEE, 0.625 mg/day for 8
weeks, to diabetic postmenopausal women had effects on
LDL and HDL cholesterol levels and LDL/HDL ratios
comparable to those achieved in both healthy postmeno-
pausal women in our previous studies (6,23,24,29) and type
II diabetic postmenopausal women in other studies (17,33).
Of interest, serum triglyceride levels in this study increased
to a similar extent to that in both our previous studies
(6,23,24) and other studies (17,33) after estrogen. The
reduction of glycosylated hemoglobin with CEE was con-
sistent with that found in other studies (34,35).
Effect of therapies on NO bioactivity. In contrast to
previous reports observing estrogen’s effect of improving
endothelium-dependent dilation in healthy postmenopausal
women (8,23,24,36), endothelium-dependent dilation was
not improved by estrogen in type II diabetic postmeno-
pausal women, despite similar effects of estrogen on lipopro-
tein levels, in the current study. Given the SD of 3.12% of
the differences in flow-mediated dilation between CEE and
placebo, the statistical power to accept our observation was
81.5%. Indeed, in our previous study, CEE at a dose of only
0.625 mg improved brachial artery flow-mediated vasodila-
tion from 4.3% to 8.8% in healthy postmenopausal women
(23). Our observation is consistent with those of several
recent groups (19,37–40). However, the same dose of CEE
increased brachial artery flow-mediated vasodilation just a
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little bit, from 5.87% to 6.52%, in the current study. In a
very recent report on premenopausal women, diabetes led to
endothelial dysfunction similar to that observed in diabetic
men, suggesting no protective effect of estrogen on CAD
and mortality in diabetic postmenopausal women (40).
Other investigators reported an improvement in endothelium-
independent dilation with CEE therapy; however, the im-
provement was related to a direct smooth muscle effect of
supraphysiologic doses of CEE, 1.25 to 5 mg/day, and the
magnitude of the response was much greater, from 14.6% to
21.2% (41). In our previous studies (23,24,29) and another (8)
using commonly used dosages, endothelium-independent di-
lation was not increased with estrogen therapy. Accordingly,
the apparently greater effect of CEE on endothelium-
independent dilation in the current study was small and of
marginal statistical significance, and therefore may not be
biologically significant.
Effect of therapies on markers of inflammation. To gain
additional insight into the mechanisms of the potentially
vasculoprotective effects of estrogen in type II diabetic
postmenopausal women, we measured markers of inflam-
mation, hemostasis, fibrinolytic inhibition and plaque sta-
bility that, according to clinical and experimental studies,
are potentially affected by estrogen in healthy postmeno-
pausal women (6,23,24,29,42).
Serum levels of E-selectin, ICAM-1 and VCAM-1 have
been reported to be higher in postmenopausal women with
CAD not treated with hormones than in postmenopausal
women with CAD treated with hormones at the time of
cardiac catheterization (43). Of interest, Nathan et al. (44)
demonstrated, in vivo, that there was a gender difference in
monocyte adhesion to endothelial cells and transendothelial
migration after hypercholesterolemia, and that this gender
difference was partly due to estradiol. They suggested that
estradiol inhibited monocyte adhesion by inhibiting expres-
sion of VCAM-1. Diabetes is associated with increased
adhesion molecule expression and enhanced adhesion of
platelets and monocytes (12). In the current study, baseline
levels of E-selectin, ICAM-1 and VCAM-1 were higher
than those in healthy postmenopausal women
(23,24,29,42). We observed that estrogen did not signifi-
cantly change E-selectin, ICAM-1 or VCAM-1 levels,
which is consistent with no significant improvement in NO
bioactivity. This observation is in contrast to our previous
findings in healthy postmenopausal women (23,24,29,42).
One study observed that diabetic postmenopausal women
receiving hormone replacement therapy had lower ICAM-1
levels, as compared with diabetic postmenopausal women
without hormone replacement therapy (19). However, this
study was a cross-sectional study, and furthermore, the
number of patients in each group was small. Frazier-Jessen
et al. (45) observed that estradiol inhibited lipopolysaccharide-
stimulated JE/MCP-1 messenger ribonucleic acid (mRNA)
expression in ANA-1 and J774A.1 murine macrophage cell
lines. This observation was confirmed by Pervin et al. (46),
who observed that the cholesterol-induced increase in
MCP-1 protein and mRNA expression was significantly
attenuated in ovariectomized rabbits supplemented with
estradiol pellets. However, we found that estrogen did not
significantly reduce MCP-1 levels in type II diabetic post-
menopausal women.
Effect of therapies on hemostasis and fibrinolytic inhibi-
tion. We have previously demonstrated that in postmeno-
pausal women, oral CEE reduced PAI-1 levels, with con-
comitant increases in the levels of D-dimer, a product of
cross-linked fibrin degradation by plasmin, thus providing
evidence of enhanced fibrinolysis (6). However, as activation
of coagulation pathways has been detected in postmeno-
pausal women treated with estrogen therapy (47,48), poten-
tiation of fibrinolysis could be a consequence of activation of
coagulation pathways as the primary response to estrogen
administration. We found that the increases in fibrinolytic
potential (tissue-type plasminogen activator:PAI-1) did not
correlate with the minimal changes observed in prothrom-
bin fragment 12 or thrombin-antithrombin levels after
CEE in healthy postmenopausal women (49). The Heart
and Estrogen/progestin Replacement Study (HERS) ob-
served that more women in the hormone-treated group
experienced deep vein thromboses and pulmonary emboli. It
is noteworthy that the risk of venous thromboemboli in
postmenopausal women randomized to placebo was 10-
fold higher than that previously reported (50). One-third of
HERS participants was diabetic. Impaired fibrinolytic ac-
tivity and increased endothelial cell procoagulant activity
were observed in diabetics (12,22). We measured variables
of coagulation activation—TF antigen and activity—and
variables of fibrinolytic potentiation—PAI-1 antigen lev-
els—in the current study. Oxidized LDL enhanced
lipopolysaccharide-induced TF expression in human adher-
ent monocytes (27) and stimulated the synthesis and release
of PAI-1 from endothelial cells in culture (51). We observed
that estrogen tended to decrease TF antigen and increase
TF activity levels and lower plasma PAI-1 levels in the current
study. However, the effect of estrogen on PAI-1 was less
apparent in healthy postmenopausal women (6,23,24,29).
Effect of therapies on plaque stability. Hyperglycemia
alters endothelial cell matrix production, which may con-
tribute to basement membrane thickening (12,52). Hyper-
glycemia increased endothelial cell collagen and fibronectin
synthesis (52). Estrogen may inhibit the expression and
activity of MMP by both decreasing LDL cholesterol and
increasing HDL cholesterol. Indeed, Xu et al. (53) demon-
strated that oxidized LDL upregulated MMP-9 expression
while reducing tissue inhibitor of MMP-1 in monocyte-
derived macrophages. Furthermore, HDL abrogated oxi-
dized LDL-induced MMP-9 expression. Therefore, estro-
gen may favor plaque stabilization as a plausible mechanism
to prevent atherosclerosis in healthy postmenopausal
women. However, we found that estrogen did not signifi-
cantly lower plasma MMP-9 levels.
Conclusions. Although all patients had type II diabetes
mellitus, and the majority were overweight, the levels of
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hyperinsulinemia and insulin resistance were not deter-
mined in the present study. In addition, other factors that
could influence endothelial function (e.g., oxidized LDL)
were not measured. Therefore, our observations support the
in vitro and in vivo animal data (18,54).
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